{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:30:00Z","timestamp":1793705400640,"version":"4.5.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Duchenne muscular dystrophy (DMD) is a severe X-linked muscle wasting disease with childhood onset that leads to loss of ambulation in the teenage years and mortality in the second or third decade of life. Prior to 10 years ago, disease-modifying pharmacologic intervention was limited to glucocorticoid steroids. However, in the past decade, several new medications have been approved for use in DMD. These medications work by different mechanisms along the disease pathway that lead to progressive muscle damage in DMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Seven new medications for DMD have been approved for use by the United States Food and Drug Administration since 2016. These include vamorolone (AGAMREE), which is a novel dissociative glucocorticoid; eteplirsen (EXONDYS 51), golodirsen (VYONDYS 53), vitolarsen (VILTEPSO) and casimersen (AMONDYS-45), which are the so-called \u2018exon skipping\u2019 phosphorodiamidate morpholino oligomers or antisense oligonucleotides; delandistrogene moxeparvovec (ELEVIDYS), which is a microdystrophin gene transfer therapy; and givinostat (DUVYZAT), which is a histone deacetylase inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review summarizes the mechanism of action, key safety considerations and available evidence on motor function impact that these novel medications have demonstrated in DMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001558","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:01:53Z","timestamp":1775052113000},"page":"604-608","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Treatment advances for Duchenne muscular dystrophy"],"prefix":"10.1097","volume":"38","author":[{"given":"Alexander","family":"Zygmunt","sequence":"first","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center"},{"name":"University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Tian","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center"},{"name":"University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of Duchenne and Becker muscular dystrophies in the United States","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"1183101","DOI":"10.3389\/fphys.2023.1183101","article-title":"Duchenne muscular dystrophy: disease mechanism and therapeutic strategies","volume":"14","author":"Bez Batti Angulski","year":"2023","journal-title":"Front Physiol"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"R6-20261103","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol Res"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne Muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/jcph.1388","article-title":"Population pharmacokinetics of vamorolone (VBP15) in healthy men and boys with Duchenne muscular dystrophy","volume":"59","author":"Mavroudis","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse drug reactions and toxicity of the food and drug administration-approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"R16-20261103","first-page":"145","article-title":"Eteplirsen (Exondys 51) for Duchenne muscular dystrophy","volume":"58","year":"2016","journal-title":"Med Lett Drugs Ther"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI Trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-210665","article-title":"A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term eteplirsen treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mus.28075","article-title":"Survival among patients receiving eteplirsen for up to 8\u200ayears for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls","volume":"70","author":"Iff","year":"2024","journal-title":"Muscle Nerve"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"R21-20261103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-term safety and efficacy data of golodirsen in ambulatory patients with duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther"},{"key":"R22-20261103","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"R23-20261103","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JND-221656","article-title":"Efficacy and safety of viltolarsen in boys with duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study","volume":"10","author":"Clemens","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/biomedicines12040912","article-title":"Casimersen (AMONDYS 45): an antisense oligonucleotide for duchenne muscular dystrophy","volume":"12","author":"Assefa","year":"2024","journal-title":"Biomedicines"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"R27-20261103","doi-asserted-by":"crossref","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2\u200ayears posttreatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"R28-20261103","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat Med"},{"key":"R29-20261103","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"R30-20261103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","article-title":"Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy","volume":"153","author":"Mendell","year":"2024","journal-title":"Pediatr Neurol"},{"key":"R31-20261103","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","article-title":"Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy","volume":"15","author":"Potter","year":"2025","journal-title":"Sci Rep"},{"issue":"(Pt 3)","key":"R32-20261103","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem J"},{"key":"R33-20261103","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/epi.14.36","article-title":"Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy","volume":"6","author":"Consalvi","year":"2014","journal-title":"Epigenomics"},{"key":"R34-20261103","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"R35-20261103","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOP.0000000000001558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:00:33Z","timestamp":1793703633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MOP.0000000000001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001558","relation":{},"ISSN":["1531-698X","1040-8703"],"issn-type":[{"value":"1531-698X","type":"electronic"},{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}